<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658188</url>
  </required_header>
  <id_info>
    <org_study_id>8825-CL-0005</org_study_id>
    <nct_id>NCT02658188</nct_id>
  </id_info>
  <brief_title>Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients</brief_title>
  <official_title>Long-term Study - Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of ASP8825 (gabapentin
      enacarbil) for long-term treatment of restless legs syndrome patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in IRLS score</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>IRLS: International Restless Legs Syndrome Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Vital signs</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Blood pressure and pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Adverse Events</measure>
    <time_frame>Up to Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Laboratory tests</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Hematology, blood biochemistry, thyroid function test and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by 12-lead-electrocardiogram</measure>
    <time_frame>Up to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders on ICGl of improvement</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>ICGI: Investigator-rated Clinical Global Impression of improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders on PCGI of improvement</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>PCGI: Patient-rated Clinical Global Impression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PSQI</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>PSQI: Pittsburgh Sleep Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SF-36v2</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>SF-36v2: Medical Outcomes Study 36-Item Short-Form Health Survey version 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in RLS-QOL</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>RLS-QOL: Restless Legs Syndrome Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MOS sleep scale</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>MOS: Medical outcomes study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of gabapentin</measure>
    <time_frame>Week 12, 28 and 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>ASP8825 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP8825</intervention_name>
    <description>Oral</description>
    <arm_group_label>ASP8825 group</arm_group_label>
    <other_name>gabapentin enacarbil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who diagnosed with RLS according to the diagnostic criteria established by
             the International RLS Study Group

          -  International Restless Legs Syndrome Scale (IRLS) score ≥15 presence of RLS symptoms
             on ≥15 days per month and ≥4 days per week preceding inclusion in this study

        Exclusion Criteria:

          -  Patients using dopamine agonists or gabapentin within 1 week before or any anti-RLS
             treatment within 2 weeks before the start of the pretreatment observation period

          -  Patients with an estimated creatinine clearance &lt;60 mL/min determined using the
             Cockcroft-Gault formula

          -  Pregnant or lactating women

          -  Individuals with serum ferritin &lt;20 ng/mL were also excluded from the trial

          -  Individuals with movement disorders and/or abnormal neurological findings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=8825-CL-0005</url>
    <description>Link to results on Astellas Clinical Study Results Web site</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Restless legs syndrome patients</keyword>
  <keyword>ASP8825</keyword>
  <keyword>XP13512</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

